DNA containing variant FRT sequences

Details DNA containing variant FRT sequences DNA containing variant FRT sequences

2006-06-13

2006-06-13

Sullivan, Daniel M. (Department: 1636)

Chemistry: molecular biology and microbiology

Process of mutation, cell fusion, or genetic modification

Introduction of a polynucleotide molecule into or...

C435S468000, C435S471000, C435S325000, C536S024200, C514S04400A

Reexamination Certificate

active

07060499

ABSTRACT:
To provide DNA comprising mutant FRT sequence which causes recombination reaction between two mutant FRT sequences having an identical sequence to each other but does not cause recombination reaction with a wild-type FRT sequence, in the presence of FLP recombinase; and a method for performing high-efficiency, gene insertion or gene replacement. A DNA comprising a mutant FRT sequence. A DNA comprising a mutant FRT sequence possessing (A) causing no specific DNA recombination reaction with wild type FRT, even if FLP recombinase is present, and (B) causing specific DNA recombination reaction with another mutant FRT sequence having an identical sequence thereto in the presence of recombinase FLP; gene replacement method using the DNA in the presence of recombinase FLP; and a specific DNA recombination method, characterized in that a specific DNA recombination reaction is carried out by using two mutant FRT sequences in the presence of recombinase FLP.

REFERENCES:
Dymecki SM. Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice. Proc Natl Acad Sci U S A. Jun. 11, 1996;93(12):6191-6.
Emanueli et al. Angiogenesis gene therapy to rescue ischaemic tissues: achievements and future directions.Br J Pharmacol. Aug. 2001;133(7):951-8.
Marshall E. Gene therapy's growing pains. Science. Aug. 25, 1995;269(5227):1050, 1052-5.
Rissanen et al. Gene therapy for therapeutic angiogenesis in critically ischaemic lower limb—on the way to the clinic. Eur J Clin Invest. Aug. 2001;31(8):651-66.
Ross et al. Gene therapy in the United States: a five-year status report. Hum Gene Ther. Sep. 10, 1996;7(14):1781-90.
Rubanyi GM. The future of human gene therapy. Mol Aspects Med. Jun. 2001;22(3):113-42.
Schwaab et al. Gene therapy of hemophilia. Semin Thromb Hemost. Aug. 2001;27(4):417-24.
Sigmund CD. Viewpoint: are studies in genetically altered mice out of control? Arterioscler Thromb Vasc Biol. Jun. 2000;20(6):1425-9.
Verma et al. Gene therapy—promises, problems and prospects. Nature. Sep. 18, 1997;389(6648):239-42.
Vooijs et al. Flp-mediated tissue-specific inactivation of the retinoblastoma tumor suppressor gene in the mouse. Oncogene. Jul. 9, 1998;17(1):1-12.
Eck et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 5, McGraw-Hill, NY.
Orkin et al. (1995) Report and recommendations of the panel to assess the NIH investment in research on gene therapy, available through the National Institutes of Health and at http://www.nih.gov
ews/panelrep.html.
Seibler et al., Biochemistry, vol. 36, No. 7, pp. 1740-1747 (1997).
Schlake et al., Biochemistry, vol. 33, pp. 12746-12751 (1994).
Seibler et al., Biochemistry, vol. 37, pp. 6229-6234 (1998).
Umlauf et al., The EMBO Journal, vol. 7, No. 6, pp. 1845-1852 (1988).

Affiliated with

Also associated with

Rating

DNA containing variant FRT sequences does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with DNA containing variant FRT sequences, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA containing variant FRT sequences will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3655265